Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.

This study observed that downregulation of laminin-511 plays an important role in hair regression during the catagen stage in mice.

This study demonstrated that a new topical treatment using ketotifen-loaded microneedles, designed for prolonged release, significantly reduced inflammatory markers in an animal model of allergic conjunctivitis, suggesting enhanced therapeutic delivery and sustained ocular benefits.

This article reviews approved treatments for androgenetic alopecia and reports no new research findings, highlighting the need for further studies.

This study demonstrated that the IVL-DrugFluidic® platform is effective for mass-producing finasteride-loaded polymeric microspheres for long-acting injectables, maintaining stable drug release without an initial burst for a month.

In this study, researchers identified the lncRNA MSTRG.14227.1 in cashmere goats and found it inhibits the morphogenesis of secondary hair follicles by interacting with the chi-miR-433/ADAMTS3 signaling axis, affecting cashmere yield and quality.

In this study, researchers observed that melatonin-mediated LncRNA MTC in Liaoning cashmere goat skin fibroblasts enhances cell proliferation by interacting with the GSTM1 protein, affecting its complex formation with ASK1 and thereby inhibiting apoptosis, which may be relevant for improving cashmere growth.

This study found that the Arabidopsis thaliana protein Formin 2 localizes to plasmodesmata and is crucial for regulating their permeability by anchoring actin filaments, which affects virus susceptibility.

This study investigated spanlastic nanovascular drug delivery systems and found that they can effectively enhance the transport and continuous release of medicines with small particle size, low polydispersity index, and satisfactory entrapment efficiency, showing potential as carriers for drug delivery.

This study demonstrated that the immunomodulatory drug FTY720 may enhance the survival of allogeneic fat grafts in mice by reducing immune rejection and improving neovascularization.

This study introduced a novel in vitro murine assay using transgenic mice to identify immunomodulatory compounds, which identified 160 potential hits from 4,398 compounds screened.

This study investigated the possible role of neutrophil extracellular traps in contributing to fibrosis in stenotic Crohn's disease.

This study operationalizes a four-step workflow for selecting donor hair for capsule extensions, translating surgical trichology insights into an extension-specific protocol to enhance natural hair optics and biomechanics, suitable for premium extension services.

This study found that circ 0020938 suppresses hair follicle stem cell proliferation by interacting with the miR-142-5p/DSG4 axis, which aids in the hair follicle cycle's proper progression.

This pilot clinical study introduces DEC cells as a novel therapy for Duchenne muscular dystrophy, confirming safety and efficacy in seven patients up to 24 months post-treatment.

This study found that applying both dehydrothermal treatment and carbodiimide crosslinking improved the mechanical properties of porcine acellular dermal matrix scaffolds without added cytotoxicity, suggesting potential applications in tissue engineering.

The LTF gene may help predict and manage nonspecific orbital inflammation.

This case report highlights the use of microarray analysis to identify cryptic chromosomal rearrangements in a young woman with intellectual disability and multiple congenital anomalies.

This study identified miRNAs within the Dlk1-Gtl2 region on chromosome 18 as potential epigenetic regulators of lamb fur traits, with possible implications for the PI3K-AKT signaling pathway.

In this phase I study, CT-707, a new ALK inhibitor, showed a 77% response rate among Chinese patients with advanced ALK-rearranged non-small cell lung cancer, suggesting clinical effectiveness despite some adverse events like diarrhea and liver enzyme elevation.